alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
026788 ATA MAX LOGISTICS (SHANGHAI) LTD. Failure to maintain a bond 11/4/2022

026978 BLUE LOGISTICS, S.A. Voluntary Surrender 11/30/2022

019208 DOLPHIN LOGISTICS COMPANY LIMITED Failure to maintain a bond 11/30/2022

030438 ENERGY STORAGE INTERNATIONAL LOGISTICS (NINGBO) CO.,LTD. Failure to maintain a bond 11/18/2022

030192 GOLDENWAYS SUPPLIER CHAIN CO.,LTD Failure to maintain a bond 11/8/2022

030244 GUANGDONG FEIXIANG INTERNATIONAL LOGISTICS CO., LTD. Failure to maintain a bond 11/8/2022

030233 HANGZHOU EJU INTERNATIONAL LOGISTICS LTD. Failure to maintain a bond 11/9/2022

030264 JADE CARGO LINE CO., LTD Failure to maintain a bond 11/17/2022

010345 MARITIMA EUROSHIP, S.A. Failure to maintain a bond 11/20/2022

027433 MC EXPRESS INT'L CO., LTD. Failure to maintain a bond 11/27/2022

030289 NINGBO GOLDEN SHINE INTERNATIONAL LOGISTICS CO.,LTD. Failure to maintain a bond 11/17/2022

030363 SHANGHAI CHUANHONG INTERNATIONAL TRANSPORTATION CO., LTD. Failure to maintain a bond 11/19/2022

030276 SHANGHAI DMF & WISDOM INTERNATIONAL LOGISTICS CO.,LTD Failure to maintain a bond 11/10/2022

030447 SHANGHAI E-FLY INTERNATIONAL LOGISTICS CO.,LTD. Failure to maintain a bond 11/14/2022

030295 SHANGHAI GENERAL INTERMODAL TRANSPORT CO., LTD Voluntary Surrender 11/17/2022

030286 SHANGHAI JINYU LOGISTICS CO,.LTD Failure to maintain a bond 11/23/2022

030382 SHAOXING ELATION INTERNATIONAL FREIGHT FORWARDING CO.,LTD Failure to maintain a bond 11/7/2022

025333 SHENZHEN ANDA SHUN INTERNATIONAL LOGISTICS CO., LTD. Failure to maintain a bond 11/18/2022

030445 SHENZHEN DONGHONG MRT INTERNATIONAL LOGISTICS CO.,LTD Failure to maintain a bond 11/12/2022

030537 SHENZHEN GOLDEN AGILITY LOGISTICS SERVICE CO., LTD. Failure to maintain a bond 11/28/2022

030444 SHENZHEN JETLINE INTERNATIONAL LOGISTICS CO., LTD Failure to maintain a bond 11/15/2022

030253 SHENZHEN MAIKUN EXPRESS SUPPLY CHAIN MANAGEMENT CO.,LTD Failure to maintain a bond 11/11/2022

030329 SHENZHEN SEA-LINK INTERNATIONAL FREIGHT FORWARDING CO.LTD Failure to maintain a bond 11/30/2022

030460 SHENZHEN THREE BEARS SUPPLY CHAIN MANAGEMENT CO., LTD Failure to maintain a bond 11/11/2022

030545 SHENZHEN WILLGLOBAL SCM CO.,LTD Failure to maintain a bond 11/18/2022

030513 SHENZHEN YUKON SUPPLY CHAIN CO.,LTD. Failure to maintain a bond 11/30/2022

030384 VANGUARD EXPRESS INTL LOGISTICS LIMITED Failure to maintain a bond 11/28/2022

030372 XIAMEN CHING SEN SUPPLY CHAIN CO., LTD Failure to maintain a bond 11/13/2022

030517 XIAMEN SUNJET-SHIPPING CO., LTD. Failure to maintain a bond 11/19/2022

030274 XINFA GLOBAL FORWARDING (SHENZHEN) CO., LTD. Failure to maintain a bond 11/24/2022

FEDERAL MARITIME COMMISSION

Foreign Registered NVOCC Terminations & Surrenders

November 1, 2022 to November 30, 2022
stg-ex457_728.htm



Exhibit 4.57

 

Spousal Consents

 

I, FANG Wen, (Citizen of the People's Republic of China; ID Card No.:                   ), is the lawful spouse of HAN Wei (Citizen of the People's Republic of China; ID Card No.:                   , the “My Spouse”). I hereby confirm and agree that the equity held by My Spouse presently and in the future (hereinafter referred to as “Equity and Interest”) is the personal property of My Spouse, do not form the common property of me and My Spouse and can be disposed solely by My Spouse:

 

1) The equity of Wuhan Jiayan Online Education Technology Co. (the “Wuhan Jiayan”);

 

I hereby unconditionally and irrevocably waive any foregoing Equity and Interest, or any rights or Equity and Interest of the corresponding assets thereof which may be granted to me by any applicable laws, promise not to propose any claim regarding the foregoing Equity and Interest and the corresponding assets thereof, including proposing that the any of the foregoing Equity and Interest and its corresponding assets constitute the common property of me and My Spouse, and based upon such proposition, further claiming to participate in the routine operation management of the Shareholding Platform or Wuhan Jiayan or affecting in any manner any decision made by My Spouse.

 

I further confirm, promise and warrant that under any circumstance, My Spouse shall have the right to independently dispose any of the foregoing Equity and Interest he holds, and that I will not take any action that may affect or prevent the performance by My Spouse of the obligations under any transaction or transaction documents in connection with the foregoing Equity and Interest (including but not limited to, the series of controlling agreements signed by Wuhan Jiayan and its shareholders and Wuhan Studyvip Online Education Co. Limited).

 

The conclusion, validity, interpretation, performance, modification, termination and dispute settlement shall be governed by the laws of China. All parties to this Letter agree that any dispute arising out of the interpretation and performance of this Spousal Consents shall be firstly settled through amicable negotiations, or in case it cannot be settled within Thirty (30) days after one party issues a written notice to the other parties to the effect of requesting settlement through negotiations, either party may submit the dispute to China International Economic and Trade Arbitration Commission for arbitration subject to its then-currently effective arbitration rules. The arbitration shall be conducted at Beijing. The language of the arbitration shall be in English. The arbitration award shall be final and binding upon the parties.

 

 

This Spousal Consents is signed on the April 23, 2021.

 

 

[The remainder of this page is intentionally left blank]

 




 



 

 

 

[This page is the signature page to the Spousal Consents]

 


	
Signature:
	
/s/ FANG Wen

	
Name:
	
FANG Wen




 

 


	
HAN Wei hereby agrees and accepts this Spousal Consents:

	
Signature:
	
/s/ HAN Wei

	
Name:
	
HAN Wei




 

  

Spousal Consents - Signature Page
Wilshire Credit Corporation
Payments
P.O. Box 30040; Los Angeles, CA  90030-0040
or   P.O. Box 650314; Dallas, TX  75265-0314
Correspondence

P.O. Box 8517; Portland, OR  97207-8517
Phone

(503) 952-7947
(888) 502-0100
Fax

(503) 952-7476
Web Site

www.wfsg.com
Exhibit 31
[Wilshire logo] Exhibit S
SARBANES-OXLEY CERTIFICATION
March 1, 2007
Merrill Lynch Mortgage Investors, Inc. 250 Vesey Street 4 World Financial Center, 10
th
Floor
New York, New York  10080
U.S. Bank National Association 60 Livingston Avenue Mail Code EP-MN-WS3D St. Paul, Minnesota 55107-2292 Attn: Structured Finance/SURF 2006-AB1
Re:
Specialty Underwriting and Residential Finance Trust, Mortgage Loan Asset-Backed Certificates, Series 2006-AB1,

Pool 1406

I, Ken Frye, Senior Vice President, Loan Servicing, certify that:
1.

I, or persons under my supervision, have reviewed the report on Form 10-K and all reports on Form 10-D
required to be filed in respect of the period covered by this report on Form 10-K of Merrill Lynch Mortgage Investors, Inc., Depositor (the "Exchange Act periodic reports");
2.

Based on my knowledge, the Exchange Act periodic reports does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.

Based on my knowledge, all of the distribution, servicing and other information required to be provided under
Form 10-D for the period covered by this report is included in the Exchange Act periodic reports;
4.

I am responsible for reviewing the activities performed by the Servicer and based on my knowledge and the
compliance review conducted in preparing the Servicer compliance statement required by this report under Item 1123 of Regulation AB, and except as disclosed in the Exchange Act periodic reports, the Servicer has fulfilled its obligations under the Servicing Agreement; and
5.

All of the reports on assessment of compliance with servicing criteria for ABS and their related attestation
reports on assessment of compliance with servicing criteria for asset-backed securities required to be included in this report in accordance with Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to this report, except as otherwise disclosed in this report.  Any material instances of noncompliance described in such reports have been disclosed in this report on Form 10-K.

In giving the certifications above, I have reasonably relied on information provided to me by the Trustee, U.S.
Bank National Association, an unaffiliated party.
Wilshire Credit Corporation,as Servicer
By:__/s/__Ken Frye____________ Name: Ken Frye Title: Senior Vice President Loan Servicing (senior officer in charge of the servicing function of the servicer)
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 23-2276

BRYAN YANCEY,

Plaintiff - Appellant,

v.

GENERAL MOTORS FINANCIAL,

Defendant - Appellee.

Appeal from the United States District Court for the Eastern District of Virginia, at 

Alexandria. Michael Stefan Nachmanoff, District Judge. (1:23-cv-01167-MSN-IDD)

Submitted: August 27, 2024 Decided: August 29, 2024

Before KING and BENJAMIN, Circuit Judges, and KEENAN, Senior Circuit Judge.

Affirmed by unpublished per curiam opinion.

Bryan Yancey, Appellant Pro Se. Alan Daniel Leeth, BURR & FORMAN, LLP, 

Birmingham, Alabama, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

USCA4 Appeal: 23-2276 Doc: 13 Filed: 08/29/2024 Pg: 1 of 2
2

PER CURIAM:

Bryan Yancey appeals the district court’s order granting Defendant’s motion to 

dismiss Yancey’s breach of contract claims. We have reviewed the record and find no 

reversible error. Accordingly, we affirm the district court’s order. Yancey v. Gen. Motors 

Fin., No. 1:23-cv-01167-MSN-IDD (E.D. Va. Nov. 2, 2023). We deny as moot Yancey’s 

motion to expedite. We dispense with oral argument because the facts and legal 

contentions are adequately presented in the materials before this court and argument would 

not aid the decisional process.

AFFIRMED

USCA4 Appeal: 23-2276 Doc: 13 Filed: 08/29/2024 Pg: 2 of 2
Exhibit 31.2
 Certification Pursuant to Rule 13a-14(a) of the Exchange Act
 
 I, John R. Emery, Chief Financial Officer of Ventiv Health, Inc., certify that:
 
 1.  I have reviewed this quarterly report on Form 10-Q of Ventiv Health, Inc.;
 
 2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
 
 3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
 
 4.  The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
 
 a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 
 b)  evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 c)  disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect the registrants internal control over financial reporting; and
 
 5.  The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors:
 
 a)  all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
 
 b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
  
 DATE: May 6, 2004

By:

/S/    JOHNR. EMERYJohn R. Emery
Chief Financial Officer
AMENDMENT
      NO. 1 TO

     

    PLACEMENT
      AGENCY AGREEMENT

     

    THIS
      AMENDMENT, dated December 28, 2006 (this “Amendment”), between Capital
      Growth Systems, Inc.,
      a
      Florida corporation
      d/b/a
      Connectivity Solutions International Inc. (the
      “Company”), and National
      Securities Corporation
      (the
“Placement Agent”).

     

    W
      I T N E S S E T H

     

    WHEREAS,
      the parties hereto have heretofore entered into a Placement Agency Agreement,
      dated November 14, 2006 (the “Agreement”); and

     

    WHEREAS,
      the Company and the Placement Agent wish to amend the Agreement to, among other
      things, the reflect the increasing of the Minimum Amount and Maximum Amount
      of
      Escrow Funds needed to be raised in the Company’s Offering of its
      Units.

     

    NOW,
      THEREFORE, the parties hereto, in consideration of the mutual promises herein
      contained and for other good and valuable consideration, the receipt and
      sufficiency of which is hereby acknowledged, hereby agree to amend the Agreement
      as follows:

     

    1
      1. Definitions;
      References; Continuation of Agreement.
      Unless
      otherwise specified herein, each term used herein that is defined in the
      Agreement shall have the meaning assigned to such term in the Agreement. Each
      reference to “hereof,” “hereto,” “hereunder,” “herein” and “hereby” and each
      other similar reference, and each reference to “this Agreement” and each other
      similar reference, contained in the Agreement shall from and after the date
      hereof refer to the Agreement as amended hereby. Except as amended hereby,
      all
      terms and provisions of the Agreement shall continue unmodified and remain
      in
      full force and effect.

     

    2. Definition
      Clarified.
      The
      term “Minimum Amount” as defined in the Agreement shall be 150 Units
      ($15,000,000) and the Term “Maximum Amount” as defined in the Agreement shall be
      300 Units ($30,000,000).

     

    3. Counterparts.
      This
      Amendment may be executed in counterparts, all of which shall be one, and the
      same, agreement.

     

    4. Governing
      Law.
      This
      Amendment shall be governed by and construed in accordance with the laws of
      the
      State of New York.

     

    


     

    


     

    (Signature
      page to follow)

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    


    IN
      WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly
      executed on the date first above written.

     

    
      	NATIONAL SECURITIES
              CORPORATION	 	CAPITAL GROWTH SYSTEMS,
              INC.
	 	 	 	 	 
	 	 	 	 	 
	
              By:

            	  	 	
              By:

            	 
	 	Brian Friedman	 	 	Thomas G. Hudson
	 	Director of Corporate Finance	 	 	Chief Executive
              Officer


    

     

     

     

    1029928_2

     

    
      
         

      

      
        2
[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Page 49388]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23178]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Segmented Metallic Guidewires

    Description of Technology: The invention pertains to segmented 
metallic guidewires that are suitable for MRI catheterization. 
Guidewires contain plurality of short conductive metallic segments that 
are individually short enough to not resonate during MR imaging. The 
conductive segments are electrically insulated from each other and 
mechanically coupled together end-to-end via connectors, such as 
stiffness matched connectors, to provide a sufficiently long, strong, 
and flexible guidewire for catheterization that is non-resonant during 
MRI.
    Potential Commercial Applications: Endovascular interventions.
    Inventors: Robert Lederman, Ozgur Kocaturk, Burcu Basar (NHLBI).
    Intellectual Property: HHS Reference No. E-253-2014/0, U.S. 
Provisional Patent Application 61/066,167 filed October 20, 2014, 
International Patent Application PCT/US2015/056266 filed October 19, 
2015, European Patent Application 15787824.0 October 19, 2015 and U.S. 
Patent Application 15/514,744 filed March 27, 2017.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
<a href="/cdn-cgi/l/email-protection#0a7962676366657c674a646362246d657c"><span class="__cf_email__" data-cfemail="3c4f54515550534a517c525554125b534a">[email protected]</span></a>.

    Dated: October 18, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-23178 Filed 10-24-17; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 99.2

CERTIFICATION PURSUANT TO  18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of LaBranche & Co Inc. (the "Company") on Form 10-Q for the period ended March 31,
2003, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Harvey S. Traison, Senior Vice President and Chief Financial Officer of the Company, hereby certify,
pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, and to the best of my knowledge, that:



|Date: May 14, 2003 |  |  | /s/HARVEY S. TRAISONName: Harvey S. Traison
Title: Senior Vice President and Chief
Financial Officer
|------------------ |  |  | ----------------------------------------------------------------------------------------------------

A signed original of this written statement required by Section 906 has been provided to LaBranche & Co Inc. and will be retained by LaBranche &
Co Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

---

QuickLinks
Exhibit 4.45
​
Supplementary Agreement to Proprietary Technology License Agreement
​
This Supplementary Agreement to the Licensing Proprietary Technology Agreement (hereinafter "Supplementary Agreement") is made on March 1, 2022 by and between the following parties:
​
		(1)
	Giganology (Shenzhen) Ltd., a wholly foreign owned enterprise duly incorporated and validly existing under the laws of the PRC, with the registered address located at Room 8, 1AA10 Building T3, No. 011 Gaoxin South Seventh Road, Gaoxin Community, Yuehai Street, Nanshan District, Shenzhen;


​
		(2)
	Shenzhen Xunlei Networking Technologies Co., Ltd., a limited liability company established   and existing under laws of the PRC, with registered address located at 21F, Block B, Building 12, Shenzhen Bay Science and Technology Ecological Park, Nanshan District, Shenzhen, Guangdong, PRC. (“Licensee”).


​
WHEREAS:
The Licensing Proprietary Technology Agreement (hereinafter "Original License Agreement") signed on March 1, 2012 will expire on February 28, 2022, the parties hereby conclude the Supplementary Agreement as follows:
		1.
	Both parties agree to extend the term of validity of the Original License Agreement for another ten (10) years that will expire on February 29, 2032. Both parties also agree that, upon expiry of the term of validity mentioned above, this Supplemental Agreement will be renewed automatically for ten (10) years consecutively if Party A does not raise any written objection, until it is finally terminated in writing by Party A.


		2.
	This Supplementary Agreement shall become effective as of the date of signature first written above. It shall be supplemental to and have the equal legal effect with the Original License Agreement. This Supplementary Agreement shall be made in quadruplicates, two of which shall be held by each party.


​
[The reminder of this page intentionally left blank]
​
​



This page is the signing page of the Supplement Agreement to the Proprietary Technology License Agreement.
Licensor: Giganology (Shenzhen) Ltd.
​
	By:
	/s/ Wu Kening
	​

	Legal representative (Signature and Seal)
	​

	/s/Seal of Giganology (Shenzhen) Ltd.
	​



​
​
Licensee:Shenzhen Xunlei Networking Technologies Co., Ltd.
​
	By:
	/s/ Wu Kening
	​

	Legal representative (Signature and Seal)
	​

	/s/Seal of Shenzhen Xunlei Networking Technologies Co., Ltd.
	​



​
#### Shackleford *vs.*Twiggs.

The granting of an injunction and the appointment of a receiver res t largely in the discretion of the chancellor, and it would require a strong case to warrant this court in interfering with such discretion. Under the allegations in the bill and answer, in connection with the affidavits read at the hearing, there was no abuse of discretion in appointing a receiver in this case.

Judgment affirmed.

March 17, 1885.

Blandford, Justice.

[This was a bill to set aside a contract of rent for fraud, and to have a receiver and injunction pending the case, insolvency being alleged. The answer denied the fraud alleged. On the bill, answer and conflicting affidavits, the chancellor granted the injunction and appointed a receiver. Defendant excepted.] ■